TLSATiziana Life Sciences Ltd

Nasdaq tizianalifesciences.com


$ 0.85 $ -0.03 (-3 %)    

Tuesday, 02-Jul-2024 15:50:02 EDT
QQQ $ 486.52 $ 5.06 (1.05 %)
DIA $ 393.25 $ 1.83 (0.47 %)
SPY $ 548.30 $ 3.67 (0.67 %)
TLT $ 90.61 $ 0.70 (0.78 %)
GLD $ 215.57 $ -0.01 (0 %)
$ 0.859
$ 0.86
$ 0.00 x 0
$ 0.00 x 0
$ 0.85 - $ 0.89
$ 0.41 - $ 1.05
178,512
na
88.55M
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tiziana-life-sciences-reports-six-month-qualitative-results-for-all-10-non-active-secondary-progressive-multiple-sclerosis-patients-enrolled-in-intermediate-size-patient-population-expanded-access-program

Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded A...

 tiziana-life-sciences-reports-3-month-neuroimaging-scores-in-multiple-sclerosis-patients-receiving-intranasal-foralumab-a-primary-endpoint-with-clinical-measures-of-edss-disability-and-mfis-fatigue-is-currently-underway

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...

 tiziana-life-sciences-announces-fda-allowance-for-additional-patients-to-be-enrolled-in-intranasal-foralumab-multiple-sclerosis-expanded-access-program

Program to expand from 10 patients to a total of 30 patients.

 tiziana-life-sciences-announces-additional-clinical-improvements-among-multiple-sclerosis-patients-in-its-expanded-access-program

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...